Austrian researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has ...

Reichel et al. SARCOSYL-PAGE: a new method for the detection of MIRCERA- and EPO-doping in blood. Drug Testing and Analysis , 2009 DOI: 10.1002/dta.97 Cite This Page : ...

It's looking good for Amgen . On Wednesday, the biotech company said a Boston Federal District Court ruled that a Roche Holding anemia drug violates one of Amgen 's patents. Amgen investors ...

For the 58 patients, the average MPG-EPO dose was 2.45 g/kg/dose (range 0.9 kg/dose to 6 kg/dose) and mean hemoglobin was 10.38 g/dL (range 7 g/dL to 13.9 g/dL).

The manufacturer of third generation EPO, CERA, is helping the World Anti-Doping Agency (WADA) track down illegal use of the drug by athletes. Roche Holding AG said that it has collaborated with ...

Roche Pharmaceuticals quickly rejected claims that Roche planted secret molecule in Mircera which allowed for detection of the CERA class drug at the 2008 Tour de France.John Fahey, WADA president ...

Roche plans to launch its anemia drug Mircera immediately in the U.K. and Germany, ... The approval, while expected, could usher in a shake-up in the epo market in Europe, ...

An injunction granted by a US district court, which addresses issues of patent infringement and public interest, prevents the US marketing of Roche's anti-anaemia drug Mircera (methoxy ...

The U.S. Food and Drug Administration issued just an approvable letter for Roche's Mircera, ... The EPO class got some surprisingly negative news earlier this month when the FDA's oncologic ...